"The benefits of orphan status are considerable," wrote Mr. O'Connor. Read the full blog post on TheChairmansBlog.com ( http://www.thechairmansblog.com/advaxis/daniel-oconnor/3-3-orphan-drug-requests ). About Advaxis, Inc. Advaxis is a clinical-stage biotechnology company developing the next generation of cancer immunotherapies. Advaxis's immunotherapies are based on a novel platform technology using live, attenuated bacteria to stimulate the immune system to selectively target cancer cells while reducing tumor defenses. ADXS-HPV, Advaxis's lead immunotherapy for the treatment of HPV-associated cancers, has demonstrated improved survival and objective tumor responses in a Phase 2 trial in 110 patients with recurrent cervical cancer. Advaxis is now planning the registrational program for ADXS-HPV.